GPNMB Lentiviral Activation Particles (h): sc-402966-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- GPNMB Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- GPNMB Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GPNMB Lentiviral Activation Plasmid (h) and GPNMB Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the GPNMB promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: GPNMB Antibody (D-9): sc-271415
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPNMB Lentiviral Activation Particles (h) | sc-402966-LAC | 200 µl | $455.00 |
GPNMB (glycoprotein non-metastatic melanoma protein B) is a type I transmembrane glycoprotein enriched in myeloid lineages and osteoclasts that modulates cell adhesion, migration, and extracellular matrix remodeling. It participates in immune and inflammatory signaling programs, influences lysosomal and vesicular trafficking, and shapes tissue repair responses through cross-talk with integrin- and growth factor–associated pathways. In cancer biology, altered GPNMB expression has been linked to tumor cell invasiveness, stromal interactions, and immune microenvironment remodeling, while in neurodegeneration it is associated with activated microglia states and injury-responsive transcriptional networks. These features make GPNMB a useful node for dissecting mechanisms of myeloid polarization, osteoimmunology, and stress-adaptive cellular phenotypes in human model systems.
GPNMB Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient GPNMB upregulation across a broader range of human cell types.
GPNMB Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the GPNMB transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous GPNMB expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native GPNMB genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.